Novartis and Kite Pharma have both submitted autologous leukemia candidates for review, paving the road for the first available chimeric antigen receptor (CAR) T cell therapy.
Non-stop production shifts are among initiatives being tested by Jazz Pharmaceuticals to up supply of orphan drug Erwinaze after its CMO received an FDA warning letter.
Porton Biopharma says it is undergoing a manufacturing review to address US FDA concerns about the production of Jazz Pharmaceuticals’s orphan drug Erwinaze.
Servier has recruited CDMO MaSTherCell SA to manufacture its universal CAR-T candidate UCART19, licensed from the biotech Cellectis as an off-the-shelf cell therapy for leukemia.
The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.
Porton Biopharma has begun construction on a new bioprocess development and manufacturing facility in the UK equipped with fermentation and down-stream processing suites.
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
